SEC Form 4 · accession 0001209191-19-005216
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martha J. Carter
Officer — Chief Regulatory Officer
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 6:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $24.04 | Jan 22, 2019 | A | 31,500 | A | — | Jan 21, 2029 | Common Stock | 31,500 | 31,500 | D |
Explanation of responses
- F1This option vests as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023.